Rationale:
Osteoporosis treatment with bisphosphonates should be re-evaluated after 3–5 years of oral use or 3 years of intravenous use, and a treatment pause should be considered. Shared decision-making between patient and clinician is essential, as this concerns long-term preventive treatment.
References:
- Nasjonal prosedyre- Osteoporose: Utredning, behandling og oppfølging av A. M. Hjelle,
- E. M. Apalset, T. T. Borgen og M. Hoff https://legeforeningen.no/Fagmed/Norsk-revmatologisk-forening/Fagradets-innstillinger/Ferdige-norske-prosedyrer/
- EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. W.F. Lems et al. Ann Rheum Dis 2017.
- 2017 American College of Rheumatology Guideline for the Prevention and Treatment of
- Glucocorticoid-Induced Osteoporosis. L. Buckley et al. Arthritis Care & Research 2017.